WO2004002384A1 - Antimicrobial, silver-containing wound dressing for continuous release - Google Patents

Antimicrobial, silver-containing wound dressing for continuous release Download PDF

Info

Publication number
WO2004002384A1
WO2004002384A1 PCT/GB2003/002780 GB0302780W WO2004002384A1 WO 2004002384 A1 WO2004002384 A1 WO 2004002384A1 GB 0302780 W GB0302780 W GB 0302780W WO 2004002384 A1 WO2004002384 A1 WO 2004002384A1
Authority
WO
WIPO (PCT)
Prior art keywords
silver
dressing
wound
staining
antimicrobial
Prior art date
Application number
PCT/GB2003/002780
Other languages
French (fr)
Inventor
Phillip Bowler
David Parsons
Michael Walker
Original Assignee
Bristol-Myers Sqibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9939502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004002384(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Sqibb Company filed Critical Bristol-Myers Sqibb Company
Priority to MXPA04012644A priority Critical patent/MXPA04012644A/en
Priority to JP2004516961A priority patent/JP2005537823A/en
Priority to DE60313626T priority patent/DE60313626T2/en
Priority to CA002490847A priority patent/CA2490847C/en
Priority to DK03761700T priority patent/DK1539070T3/en
Priority to AU2003246920A priority patent/AU2003246920B2/en
Priority to EP03761700A priority patent/EP1539070B1/en
Publication of WO2004002384A1 publication Critical patent/WO2004002384A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/38Silver; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104Silver, e.g. silver sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow

Definitions

  • the present invention relates to wound dressings having antibacterial, antiviral and/or antifungal activity, to a method of producing such dressings and the use of such dressings in the treatment of wounds.
  • silver is gaining increasing popularity as an effective antimicrobial agent.
  • the advantage of using silver as an antimicrobial agent is that there is no formation of bacterial tolerance. This is in contrast for instance to many antibiotics.
  • a major drawback when using ionic or metallic silver for antimicrobial purposes is however the lack of control over release of the silver ions within and from the delivery vehicle.
  • the delivery vehicle for the silver does not limit the amount of ionic silver entering the wound fluid, for example from a gauze soaked in a solution of silver nitrate, too high a concentration of silver ions is released into the wound fluid and the silver may precipitate as inactive silver compounds such as silver chloride or silver sulphide on the wound and skin. This can result in discoloration and staining of the wound and skin tissues. Such staining has been reported to give potentially permanent pigmentation of the skin, so called argyria. It is also known to deliver silver to the wound by fragmentation of metallic silver particles from a dressing. Such dressings are sold under the trademark Acticoat. These dressings may also give rise to staining of the wound, surrounding skin and other materials such as clothes or bed linen by deposition of metallic silver.
  • a further disadvantage of bolus delivery of silver ions into the wound fluid is that ionic silver is rapidly depleted and therefore the dressing must necessarily be frequently changed to maintain a constant presence of antimicrobial agent and minimise the opportunity for infection.
  • treatments which deliver very low concentrations of silver ions such as silver sulfadiazine.
  • the repeated changing of dressings on for instance burns patients causes pain to the patient and disturbs the healing process. It may be necessary for burn wounds to be dressed for three weeks or more.
  • WO/02 43743A to Bristol-Myers Squibb describes the preparation of a material which contains one or more hydrophilic, amphoteric or anionic polymers, where the material has antimicrobial activity.
  • the material is prepared by preparing a solution comprising an organic solvent and a source of silver, subjecting the polymer to the solution to incorporate a desired silver concentration into said polymer, and subjecting the polymer during or after this step to one or more agents that bind the silver to the polymer and render it photostable upon drying.
  • the polymer is, for example, a polysaccharide and, particularly, a carboxymethylcellulose or an alginate or a mixture thereof.
  • WO/02 43743A is not concerned with skin staining caused by silver-containing wound dressings.
  • wound dressings can be prepared which give a controlled, sustained release of silver ions within the dressing and into the adjacent wound fluid to give antimicrobial activity without staining the underlying tissue.
  • the invention provides for the use of an effective amount of silver in the manufacture of a wound dressing comprising an anionic polymer, which dressing, when applied to the wound, gives a controlled release of ionic silver into the wound fluid for the prevention of staining of the underlying tissue.
  • the wound dressing for use in the present invention comprises an amphoteric, hydrophilic, anionic polymer such as polysaccharides or modified polysaccharides, polyvinylpyrrolidone, poly vinyl alcohols, poly vinyl ethers, polyurethanes, polyacrlyates, polyacrylamides, collagen, gelatin or mixtures thereof.
  • the polymers contain carboxymethycellulose (CMC) such as sodium CMC.
  • CMC carboxymethycellulose
  • the polymer can be a polysaccharide comprising a carboxymethylcellulose or alginate or a mixture of carboxymethylcellulose and alginate.
  • the polymers contain gel-forming fibres comprising sodium CMC and which can be incorporated into wound dressings such as Aquacel (ConvaTec, Skillman, NJ) .
  • the polar or ionic nature of the polymer means that the binding of positively charged silver ions (cations) is facilitated.
  • a desired final concentration of silver in the dry wound dressing is between about 0.1% and 20% by weight, for example. Preferably between 0.1% to 10% by weight and more preferably between 0.5% and 5% by weight of the dressing. Such concentrations can be achieved by the preparation method described in WO/02 43743 A.
  • a desired concentration of ionic silver released by the dressing into water is preferably less than 1.5 ppm and, more preferably, between 1.5 ppm and 0.5 ppm. Most preferably the concentration of ionic silver released by the dressing into water is about 1 ppm.
  • antimicrobial efficacy is the product of the concentration of silver ions in solution and the period of wear.
  • concentration of silver ions is restricted by their reaction with the components of wound fluid, most notably chloride ions.
  • Silver chloride is very sparingly soluble and in the environment created in the wound is likely to be as low as 1 ⁇ g/ml.
  • Ionic silver has a high affinity for the polymers forming the dressing matrix. Hydration of the dressing with wound fluid causes a slow and continuous dissociation of silver ions until a steady state of equilibrium is achieved between silver ions in solution and those bound to the dressing. Gelation of the dressing polymer(s) further limits the rate at which silver ions are lost onto the wound tissue.
  • the concentration of silver ions in wound fluid outside of the dressing remains at or slightly below the solubility limit of silver chloride. Due to this and the absence of metallic silver, the subsequent occurrence of tissue staining is much reduced. A further effect of this continuous controlled availability and reduced rate of loss of silver ions means that the weight percent of silver in the dressing is less than would be expected to maintain effective levels of silver over the wear time of the dressing.
  • the silver is preferably bound to the anionic, amphoteric, hydrophilic polymer by a polar or ionic bonding mechanism and is treated with a photostabilizing agent. Suitable agents include ammonia and chlorides.
  • the dressing is preferably in the form of a fibrous mat of the polymer but may be in the form of woven fabric or a powder or distributed within a matrix of a hydrocolloid or acrylate adhesive.
  • the dressing can be used as part of a larger dressing or a layer in a multi-layered dressing and need not be in direct contact with the wound.
  • a dressing for use in the invention and various commercial silver- containing dressings were analysed for various properties.
  • the data is presented in the table below.
  • AQUACEL-Ag samples were prepared according to the method of WO 02 43743A.
  • Weight per unit area was determined by weighing a complete dressing and dividing by its measured dimensions.
  • Loss on drying was performed gravimetrically. A minimum of lg of sample (or a whole dressing where possible) was placed in a tared dish, weighed, heated at 105° ⁇ 3°C for 6 hours, allowed to cool in a desiccator and then reweighed. Silver assay was performed using atomic absorption spectrophotometry (AAS) on a wet acid digestion. If insoluble matter was present after the digestion procedure was completed it was removed by filtration prior to assay.
  • AAS atomic absorption spectrophotometry
  • Dissolution experiments were carried out using a standard tablet dissolution apparatus. Approximately 3g of each test dressing were sealed into a pre-washed and hydrated cellulose dialysis membrane bag (Sigma D-9402). This was then loosely attached to the stirring paddle of the dissolution apparatus using plastic cable ties. The sample was lowered into the receiving vessel containing 300ml of dissolution medium at 37°C. The stirring rate was set at 60rpm. The temperature was maintained at 37°C and the dissolution medium sampled (10ml) at regular intervals. The sample volume was kept at 300ml by regularly topping up with the dissolution medium. The dissolution media used were (i) Normal saline (0.9%w/v NaCl(aq)) and (ii) purified water.
  • the free silver content of the solutions was determined directly by AAS. Normal saline was chosen to be a simple model of wound exudate in which the naturally occurring high chloride concentration would compete for available ionic silver, attempting to precipitate it from solution as insoluble silver chloride. Water was used as an alternative medium to observe the chloride free rate of silver delivery.
  • Flamazine cream is a 1% silver sulphadiazine formulation with a density of 0.975g/cm 3 (BB867 page 6)
  • Acticoat 7 and Burn products are all based polyethylene mesh coated with silver which is sprayed on.
  • Acticoat absorbent is an alginate based product again with sprayed on silver.
  • Acticoat moisture control is a foam product coated with silver.
  • Avance is a foam with a zirconium ion exchange material distributed within it.
  • Actisorb Silver 220 is a nylon bag containing a silver impregnated charcoal cloth.
  • Avance contains only trace amounts of silver. In the dissolution experiments this was found to be readily released. In a moderately exuding wound one would expect this quantity of silver to be rapidly depleted and the dressing to become ineffective in the control of microbes .
  • Actisorb Silver 220 delivers solubilised silver very sparingly and its is predicted that although microbial growth may be retarded within the charcoal cloth, this would have very little effect on reducing the bioburden of a wound.
  • the mechanism by which Flamazine works is not clearly demonstrated by these experiments. Soluble silver availability is relatively low on a weight/ weight basis, but repeated application of a large dose (weight/area) as indicated in the instructions for use will increase availability as will any surface active and lypophilic effects of the base ointment. Its action will also be complemented by the antimicrobial activity of the sulphadiazine component.
  • Dissolution experiments were performed by placing a 5x5cm piece of dressing in a vessel containing 120ml of dissolution media thermostated at 37°C.
  • the dissolution medium was sampled (25ml) at regular intervals and the volume was kept at a constant 120ml by regularly topping up with the dissolution medium.
  • the dissolution media used were (i) purified water and (ii) normal saline (0.9%w/v NaCl(aq)).
  • the silver content of the sampled solutions was determined directly by AAS.
  • Normal saline was chosen to be a simple model of wound exudate in which the naturally occurring high chloride concentration would compete for available ionic silver, attempting to precipitate it from solution as insoluble silver chloride. Water was used as an alternative medium to observe the chloride free rate of silver delivery.
  • the difference in the ppm of silver in solution in water and in saline is an indication of the amount of silver that will be precipitated as an insoluble salt when the dressing is in use.
  • a large difference such as that obtained for Acticoat Burn suggests that a large amount of precipitate will be produced in the wear time of the dressing.
  • a small difference such as that obtained for Aquacel Ag suggests that a small amount of precipitate will be produced.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides for the use of an effective amount of silver in the manufacture of a wound dressing comprising an anionic polymer, which dressing, when applied to the wound, gives a controlled release of ionic silver into the wound fluid for the prevention of staining of the underlying tissue.

Description

ANTIMICROBIAL , SILVER-CONTAINING WOUND DRESSING FOR CONTINUOUS RELEASE
The present invention relates to wound dressings having antibacterial, antiviral and/or antifungal activity, to a method of producing such dressings and the use of such dressings in the treatment of wounds.
With the rise in antimicrobial resistance and a general call to reduce the use of antibiotics, silver is gaining increasing popularity as an effective antimicrobial agent. The advantage of using silver as an antimicrobial agent is that there is no formation of bacterial tolerance. This is in contrast for instance to many antibiotics. A major drawback when using ionic or metallic silver for antimicrobial purposes is however the lack of control over release of the silver ions within and from the delivery vehicle.
In the past it has been known to deliver silver ions by the use of a simple solution of silver nitrate. It is also known to deliver silver by the use of a complex with sulfadiazine. Silver sulfadiazine is used extensively in the treatment of wounds, and particularly burns, and is incorporated in a cream base and sold under the trademark Flamazine or Salvadene. As the silver is present in such products as a complex, its solubility in wound fluid is low and hence the quantity of active silver present is also low.
By contrast, if the delivery vehicle for the silver does not limit the amount of ionic silver entering the wound fluid, for example from a gauze soaked in a solution of silver nitrate, too high a concentration of silver ions is released into the wound fluid and the silver may precipitate as inactive silver compounds such as silver chloride or silver sulphide on the wound and skin. This can result in discoloration and staining of the wound and skin tissues. Such staining has been reported to give potentially permanent pigmentation of the skin, so called argyria. It is also known to deliver silver to the wound by fragmentation of metallic silver particles from a dressing. Such dressings are sold under the trademark Acticoat. These dressings may also give rise to staining of the wound, surrounding skin and other materials such as clothes or bed linen by deposition of metallic silver.
There thus exists a need for a delivery vehicle for silver ions which controls the release of silver ions to the wound fluid so that staining is minimised but an effective concentration is maintained to give the desired antimicrobial activity.
A further disadvantage of bolus delivery of silver ions into the wound fluid is that ionic silver is rapidly depleted and therefore the dressing must necessarily be frequently changed to maintain a constant presence of antimicrobial agent and minimise the opportunity for infection. This is also true of treatments which deliver very low concentrations of silver ions such as silver sulfadiazine. The repeated changing of dressings on for instance burns patients causes pain to the patient and disturbs the healing process. It may be necessary for burn wounds to be dressed for three weeks or more. There thus exists a need for a wound dressing with sustained release of silver ions which maintains an effective concentration over a prolonged wear time without the need for frequent dressing changes.
WO/02 43743A to Bristol-Myers Squibb describes the preparation of a material which contains one or more hydrophilic, amphoteric or anionic polymers, where the material has antimicrobial activity. The material is prepared by preparing a solution comprising an organic solvent and a source of silver, subjecting the polymer to the solution to incorporate a desired silver concentration into said polymer, and subjecting the polymer during or after this step to one or more agents that bind the silver to the polymer and render it photostable upon drying. The polymer is, for example, a polysaccharide and, particularly, a carboxymethylcellulose or an alginate or a mixture thereof. WO/02 43743A is not concerned with skin staining caused by silver-containing wound dressings.
We have now found that wound dressings can be prepared which give a controlled, sustained release of silver ions within the dressing and into the adjacent wound fluid to give antimicrobial activity without staining the underlying tissue.
Accordingly, the invention provides for the use of an effective amount of silver in the manufacture of a wound dressing comprising an anionic polymer, which dressing, when applied to the wound, gives a controlled release of ionic silver into the wound fluid for the prevention of staining of the underlying tissue.
The wound dressing for use in the present invention comprises an amphoteric, hydrophilic, anionic polymer such as polysaccharides or modified polysaccharides, polyvinylpyrrolidone, poly vinyl alcohols, poly vinyl ethers, polyurethanes, polyacrlyates, polyacrylamides, collagen, gelatin or mixtures thereof. In preferred embodiments, the polymers contain carboxymethycellulose (CMC) such as sodium CMC. In one embodiment the polymer can be a polysaccharide comprising a carboxymethylcellulose or alginate or a mixture of carboxymethylcellulose and alginate. In other embodiments, the polymers contain gel-forming fibres comprising sodium CMC and which can be incorporated into wound dressings such as Aquacel (ConvaTec, Skillman, NJ) . The polar or ionic nature of the polymer means that the binding of positively charged silver ions (cations) is facilitated. We have found that a desired final concentration of silver in the dry wound dressing is between about 0.1% and 20% by weight, for example. Preferably between 0.1% to 10% by weight and more preferably between 0.5% and 5% by weight of the dressing. Such concentrations can be achieved by the preparation method described in WO/02 43743 A.
We have also found that a desired concentration of ionic silver released by the dressing into water is preferably less than 1.5 ppm and, more preferably, between 1.5 ppm and 0.5 ppm. Most preferably the concentration of ionic silver released by the dressing into water is about 1 ppm.
Whilst not wishing to be bound by theory, the inventors hereof believe that antimicrobial efficacy is the product of the concentration of silver ions in solution and the period of wear. The concentration of silver ions is restricted by their reaction with the components of wound fluid, most notably chloride ions. Silver chloride is very sparingly soluble and in the environment created in the wound is likely to be as low as 1 μg/ml. Ionic silver has a high affinity for the polymers forming the dressing matrix. Hydration of the dressing with wound fluid causes a slow and continuous dissociation of silver ions until a steady state of equilibrium is achieved between silver ions in solution and those bound to the dressing. Gelation of the dressing polymer(s) further limits the rate at which silver ions are lost onto the wound tissue. Therefore, the concentration of silver ions in wound fluid outside of the dressing remains at or slightly below the solubility limit of silver chloride. Due to this and the absence of metallic silver, the subsequent occurrence of tissue staining is much reduced. A further effect of this continuous controlled availability and reduced rate of loss of silver ions means that the weight percent of silver in the dressing is less than would be expected to maintain effective levels of silver over the wear time of the dressing. The silver is preferably bound to the anionic, amphoteric, hydrophilic polymer by a polar or ionic bonding mechanism and is treated with a photostabilizing agent. Suitable agents include ammonia and chlorides.
The dressing is preferably in the form of a fibrous mat of the polymer but may be in the form of woven fabric or a powder or distributed within a matrix of a hydrocolloid or acrylate adhesive. The dressing can be used as part of a larger dressing or a layer in a multi-layered dressing and need not be in direct contact with the wound.
The invention is illustrated by the following examples.
Example 1
Analysis of Silver-containing Dressings and treatments
A dressing for use in the invention and various commercial silver- containing dressings were analysed for various properties. The data is presented in the table below.
AQUACEL-Ag samples were prepared according to the method of WO 02 43743A.
Weight per unit area was determined by weighing a complete dressing and dividing by its measured dimensions.
Loss on drying was performed gravimetrically. A minimum of lg of sample (or a whole dressing where possible) was placed in a tared dish, weighed, heated at 105° ± 3°C for 6 hours, allowed to cool in a desiccator and then reweighed. Silver assay was performed using atomic absorption spectrophotometry (AAS) on a wet acid digestion. If insoluble matter was present after the digestion procedure was completed it was removed by filtration prior to assay.
Dissolution experiments were carried out using a standard tablet dissolution apparatus. Approximately 3g of each test dressing were sealed into a pre-washed and hydrated cellulose dialysis membrane bag (Sigma D-9402). This was then loosely attached to the stirring paddle of the dissolution apparatus using plastic cable ties. The sample was lowered into the receiving vessel containing 300ml of dissolution medium at 37°C. The stirring rate was set at 60rpm. The temperature was maintained at 37°C and the dissolution medium sampled (10ml) at regular intervals. The sample volume was kept at 300ml by regularly topping up with the dissolution medium. The dissolution media used were (i) Normal saline (0.9%w/v NaCl(aq)) and (ii) purified water. The free silver content of the solutions was determined directly by AAS. Normal saline was chosen to be a simple model of wound exudate in which the naturally occurring high chloride concentration would compete for available ionic silver, attempting to precipitate it from solution as insoluble silver chloride. Water was used as an alternative medium to observe the chloride free rate of silver delivery.
Silver Assay Data
Figure imgf000008_0001
Notes
1) Flamazine cream is a 1% silver sulphadiazine formulation with a density of 0.975g/cm3 (BB867 page 6)
2) Assuming a 4mm layer is applied per treatment as indicated in the manufacturer's instructions for use
3) LOD is an abbreviation for loss on drying
The Acticoat 7 and Burn products are all based polyethylene mesh coated with silver which is sprayed on. Acticoat absorbent is an alginate based product again with sprayed on silver. Acticoat moisture control is a foam product coated with silver. Avance is a foam with a zirconium ion exchange material distributed within it. Actisorb Silver 220 is a nylon bag containing a silver impregnated charcoal cloth.
Silver Dissolution Rate into Water (Total Volume 300cm3, stirred, 37°C) . Parts per million silver in solution (ppm) ( g/ml)
Figure imgf000009_0001
These results indicate that the silver metal-based Acticoat range of dressings would deliver high levels of solubilised silver rapidly to a moist wound where it will be precipitated as silver chloride. This dose dump effect, together with any metallic silver or silver oxide (Acticoat) will be deposited in the wound bed where it may cause cytotoxic effects and skin staining.
Avance contains only trace amounts of silver. In the dissolution experiments this was found to be readily released. In a moderately exuding wound one would expect this quantity of silver to be rapidly depleted and the dressing to become ineffective in the control of microbes .
Actisorb Silver 220 delivers solubilised silver very sparingly and its is predicted that although microbial growth may be retarded within the charcoal cloth, this would have very little effect on reducing the bioburden of a wound. The mechanism by which Flamazine works is not clearly demonstrated by these experiments. Soluble silver availability is relatively low on a weight/ weight basis, but repeated application of a large dose (weight/area) as indicated in the instructions for use will increase availability as will any surface active and lypophilic effects of the base ointment. Its action will also be complemented by the antimicrobial activity of the sulphadiazine component.
Example 2
Whole Skin Staining
Skin staining studies were carried out using an adaptation of a Franz type horizontal glass diffusion cell as described in Dugard et al, 1984. Whole human skin and wound tissue samples (1 cm2 discs) were punched out using an Osborne arch punch and placed epidermal side uppermost on the receptor chamber. The donor chamber was then gently placed on top of the receptor chamber. The whole cell was clamped together and placed into a water bath maintained at 32°C ± 1°C. The underlying whole skin was bathed in saline.
Individual silver-containing wound dressings (0.64 1 cm2) were cut out and placed onto the centre of a piece of human whole skin. 200 μl of saline was placed into the donor chamber to hydrate each dressing to mimic a moderately exuding wound. Appoximately 5-10mg of Flamazine cream was placed onto the skin and gently smoothed over the exposed skin surface by means of a small spatula. Silver nitrate solution (200 μl, 0.5%) was used as the positive control and water was used as the negative control . Each cell was left for 24 hours and images were taken using a Polaroid digital microscope camera. The results are presented in Figure 1. It can be seen that significant silver staining is obtained with silver nitrate, Acticoat Burn and Acticoat 7. There is minimal staining with Flamazine cream. Aquacel Ag was prepared as described in WO 02 43743 A. As can be seen no skin staining was obtained by the use of Aquacel Ag according to the invention.
Example 3
Wound Tissue Staining Studies
In these studies, a dressing for use in the invention, Aquacel- Ag, prepared according to WO 02 43743 A, and Acticoat 7 were applied to human ulcer tissue and left in contact with the wound for 24 hours. Saline was used as a control. The results are shown in Figure 2. The results show that no staining was obtained with use of the dressing according to the invention.
Example 4
Dissolution experiments were performed by placing a 5x5cm piece of dressing in a vessel containing 120ml of dissolution media thermostated at 37°C. The dissolution medium was sampled (25ml) at regular intervals and the volume was kept at a constant 120ml by regularly topping up with the dissolution medium. The dissolution media used were (i) purified water and (ii) normal saline (0.9%w/v NaCl(aq)). The silver content of the sampled solutions was determined directly by AAS.
Normal saline was chosen to be a simple model of wound exudate in which the naturally occurring high chloride concentration would compete for available ionic silver, attempting to precipitate it from solution as insoluble silver chloride. Water was used as an alternative medium to observe the chloride free rate of silver delivery.
Silver Dissolution Rate.
Parts per million silver in solution (ppm) (μg/ml) Water
Figure imgf000012_0001
The difference in the ppm of silver in solution in water and in saline is an indication of the amount of silver that will be precipitated as an insoluble salt when the dressing is in use. A large difference such as that obtained for Acticoat Burn suggests that a large amount of precipitate will be produced in the wear time of the dressing. A small difference such as that obtained for Aquacel Ag suggests that a small amount of precipitate will be produced.
The results indicate that the silver metal-based Acticoat Burn dressing would deliver high levels of solubilised silver rapidly to a moist wound where it would be precipitated as silver chloride. This dose dump effect, together with any metallic silver or other insoluble silver salt will be deposited in the wound bed where it may cause cytotoxic effects and skin staining. The results further indicate that Aquacel Ag will not deliver high levels of solubilised silver rapidly but will maintain a concentration of around lppm in solution throughout the wear time of the dressing.

Claims

WHAT IS CLAIMED IS:
1. Use of an effective amount of silver in the manufacture of a wound dressing comprising an anionic, amphoteric or hydrophilic polymer, which dressing, when applied to a wound site, gives a controlled release of ionic silver into the wound fluid for the prevention of staining of the underlying tissue.
2. Use of an effective amount of silver in the manufacture of a wound dressing comprising an anionic, amphoteric or hydrophilic polymer, which, when in contact with wound exudate, gives a controlled release of ionic silver into the exudate for the maintenance of an effective antimicrobial activity within the dressing throughout the wear time of the dressing.
3. Use as claimed in any preceding claim wherein the anionic, amphoteric or hydrophilic polymer is selected from the group of polysaccharides or modified polysaccharides, polyvinylpyrrolidone, poly vinyl alcohols, poly vinyl ethers, polyurethanes, polyacrylates, polyacrylamides, collagen, gelatin or mixtures thereof.
4. Use as claimed in any preceding claim wherein the dressing is in the form of fibres, or a powder or distributed within a matrix of an adhesive.
5. Use as claimed in any preceding claim wherein the dressing comprises from 0.1 to 20% by weight of silver.
6. Use as claimed in any preceding claim wherein the release of ionic silver into water is less than 1 ppm.
PCT/GB2003/002780 2002-06-28 2003-06-27 Antimicrobial, silver-containing wound dressing for continuous release WO2004002384A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA04012644A MXPA04012644A (en) 2002-06-28 2003-06-27 Antimicrobial, silver-containing wound dressing for continuous release.
JP2004516961A JP2005537823A (en) 2002-06-28 2003-06-27 Antibacterial silver-containing wound dressing for continuous release
DE60313626T DE60313626T2 (en) 2002-06-28 2003-06-27 ANTIMICROBIAL SILVER-CONTAINING WOUND ASSOCIATION FOR CONTINUOUS RELEASE
CA002490847A CA2490847C (en) 2002-06-28 2003-06-27 Antimicrobial, silver-containing wound dressing for continuous release
DK03761700T DK1539070T3 (en) 2002-06-28 2003-06-27 Continuous release antimicrobial silver-containing wound dressing
AU2003246920A AU2003246920B2 (en) 2002-06-28 2003-06-27 Antimicrobial, silver-containing wound dressing for continuous release
EP03761700A EP1539070B1 (en) 2002-06-28 2003-06-27 Antimicrobial, silver-containing wound dressing for continuous release

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0215023.3A GB0215023D0 (en) 2002-06-28 2002-06-28 Wound dressing
GB0215023.3 2002-06-28

Publications (1)

Publication Number Publication Date
WO2004002384A1 true WO2004002384A1 (en) 2004-01-08

Family

ID=9939502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/002780 WO2004002384A1 (en) 2002-06-28 2003-06-27 Antimicrobial, silver-containing wound dressing for continuous release

Country Status (13)

Country Link
US (2) US20040001880A1 (en)
EP (2) EP1825841A1 (en)
JP (1) JP2005537823A (en)
AR (1) AR039769A1 (en)
AT (1) ATE361046T1 (en)
AU (1) AU2003246920B2 (en)
CA (1) CA2490847C (en)
DE (1) DE60313626T2 (en)
DK (1) DK1539070T3 (en)
ES (1) ES2286464T3 (en)
GB (1) GB0215023D0 (en)
MX (1) MXPA04012644A (en)
WO (1) WO2004002384A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036958A2 (en) * 2007-09-18 2009-03-26 Carl Freudenberg Kg Bioresorbable nonwoven fabric made of gelatin
EP2447397A1 (en) 2010-10-29 2012-05-02 Carl Freudenberg KG Non-woven fabrics made of synthetic polymers and rotation spinning method for producing same
WO2016055839A1 (en) 2014-10-10 2016-04-14 Uab "Biocentras" Extraction of enzyme complexes from streptomyces gougerotii 101, preparation of multienzyme biopreparations and their application
WO2016206638A1 (en) * 2015-06-25 2016-12-29 佛山市优特医疗科技有限公司 Wound dressing containing silver chelate fiber

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009586A1 (en) * 2000-02-29 2007-01-11 Cohen Kelman I Wound dressings containing complexes of transition metals and alginate for elastase sequestering
AU2002219937B9 (en) 2000-11-29 2006-03-16 Convatec Technologies Inc. Light stabilized antimicrobial materials
US7842306B2 (en) 2003-08-14 2010-11-30 Milliken & Company Wound care device having fluid transfer properties
US7335613B2 (en) * 2004-04-08 2008-02-26 Rohm And Haas Company Fiber substrate with antibacterial finish and methods of making and using the same
WO2006026573A2 (en) * 2004-08-30 2006-03-09 Southwest Research Institute Biocidal fibrous and film materials utilizing silver ion
DE602006000082T2 (en) * 2005-07-07 2008-05-15 Rohm And Haas Co. Fiber with antimicrobial composition
AU2006222708A1 (en) * 2005-10-07 2007-04-26 Rohm And Haas Company Method for disinfecting or sanitizing a surface
GB0525504D0 (en) 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
DE102005060461A1 (en) * 2005-12-17 2007-07-12 Paul Hartmann Ag Medical composition
GB0603487D0 (en) * 2006-02-22 2006-04-05 Agt Sciences Ltd Delivery means
US8512294B2 (en) * 2006-07-28 2013-08-20 Becton, Dickinson And Company Vascular access device antimicrobial materials and solutions
US20100081740A1 (en) * 2008-09-29 2010-04-01 Christian Jackson Aqueous inkjet ink comprising self-dispersing pigment
WO2010099182A1 (en) * 2009-02-25 2010-09-02 Board Of Regents Of The University Of Nebraska Activated creatinine and precursors as antibacterial agents, compositions and products containing such agents and uses thereof
US9232805B2 (en) 2010-06-29 2016-01-12 Biocure, Inc. In-situ forming hydrogel wound dressings containing antimicrobial agents
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
IT1407868B1 (en) * 2011-02-15 2014-05-16 Fidia Farmaceutici "ABSORBENT MEDIATION WITH ANTIDOLORIFIC ACTIVITY"
US20130264277A1 (en) * 2012-04-04 2013-10-10 Pall Corporation Antimicrobial filter
CA2895896A1 (en) 2012-12-20 2014-06-26 Convatec Technologies Inc. Processing of chemically modified cellulosic fibres
GB2511528A (en) 2013-03-06 2014-09-10 Speciality Fibres And Materials Ltd Absorbent materials
KR101810079B1 (en) * 2015-06-01 2017-12-19 주식회사 아모그린텍 Antibacterial dressing
KR101927855B1 (en) 2015-10-16 2018-12-11 주식회사 아모라이프사이언스 Dry pad
US20190351095A1 (en) 2018-05-21 2019-11-21 Milliken & Company Wound care device having fluid transfer and adhesive properties
US20190351094A1 (en) 2018-05-21 2019-11-21 Milliken & Company Wound care device having fluid transfer and adhesive properties

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328421A2 (en) * 1988-02-11 1989-08-16 The Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
EP0797965A1 (en) * 1990-06-14 1997-10-01 Vitaphore Corporation Wound dressing and catheter securing using a polyurethane-biopolymer composite
WO2002043743A1 (en) * 2000-11-29 2002-06-06 Bristol-Myers Squibb Company Light stabilized antimicrobial materials

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333093B1 (en) * 1997-03-17 2001-12-25 Westaim Biomedical Corp. Anti-microbial coatings having indicator properties and wound dressings
US6267782B1 (en) * 1997-11-20 2001-07-31 St. Jude Medical, Inc. Medical article with adhered antimicrobial metal
US6592888B1 (en) * 2000-05-31 2003-07-15 Jentec, Inc. Composition for wound dressings safely using metallic compounds to produce anti-microbial properties

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328421A2 (en) * 1988-02-11 1989-08-16 The Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
EP0797965A1 (en) * 1990-06-14 1997-10-01 Vitaphore Corporation Wound dressing and catheter securing using a polyurethane-biopolymer composite
WO2002043743A1 (en) * 2000-11-29 2002-06-06 Bristol-Myers Squibb Company Light stabilized antimicrobial materials

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P. NATHAN ET AL.: "A clinical study", THE JOURNAL OF TRAUMA, vol. 22, no. 12, December 1982 (1982-12-01), united states, pages 1015 - 1018, XP009018524 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2409718A1 (en) 2007-09-18 2012-01-25 Carl Freudenberg KG Bioresorbable nonwoven fabric made of gelatin
DE202007019670U1 (en) 2007-09-18 2015-04-01 Carl Freudenberg Kg Bioresorbable wound dressings
DE102007044648A1 (en) 2007-09-18 2009-04-09 Carl Freudenberg Kg Bioresorbable gelatin nonwoven
WO2009036958A3 (en) * 2007-09-18 2010-02-25 Carl Freudenberg Kg Bioresorbable nonwoven fabric made of gelatin
EP2042199A3 (en) * 2007-09-18 2011-09-14 Carl Freudenberg KG Bioresorbable wound dressings
AU2008300873B2 (en) * 2007-09-18 2011-11-10 Carl Freudenberg Kg Bioresorbable nonwoven fabric made of gelatin
EP2042199A2 (en) 2007-09-18 2009-04-01 Carl Freudenberg KG Bioresorbable wound dressings
DE102007044648B4 (en) * 2007-09-18 2020-11-26 Carl Freudenberg Kg Bioresorbable gelatin non-woven fabric
WO2009036958A2 (en) * 2007-09-18 2009-03-26 Carl Freudenberg Kg Bioresorbable nonwoven fabric made of gelatin
CN101861173B (en) * 2007-09-18 2014-06-18 卡尔·弗罗伊登伯格公司 Bioresorbable nonwoven fabric made of gelatin
US10624985B2 (en) 2007-09-18 2020-04-21 Carl Freudenberg Kg Bioresorbable nonwoven fabric made of gelatin
EP2447397A1 (en) 2010-10-29 2012-05-02 Carl Freudenberg KG Non-woven fabrics made of synthetic polymers and rotation spinning method for producing same
WO2012055494A1 (en) 2010-10-29 2012-05-03 Carl Freudenberg Kg Nonwoven materials made of synthetic polymers and rotary spinning method for manufacturing same
WO2016055839A1 (en) 2014-10-10 2016-04-14 Uab "Biocentras" Extraction of enzyme complexes from streptomyces gougerotii 101, preparation of multienzyme biopreparations and their application
WO2016206638A1 (en) * 2015-06-25 2016-12-29 佛山市优特医疗科技有限公司 Wound dressing containing silver chelate fiber

Also Published As

Publication number Publication date
CA2490847C (en) 2008-06-10
ES2286464T3 (en) 2007-12-01
GB0215023D0 (en) 2002-08-07
US20070286895A1 (en) 2007-12-13
EP1825841A1 (en) 2007-08-29
AU2003246920B2 (en) 2008-12-18
JP2005537823A (en) 2005-12-15
MXPA04012644A (en) 2005-03-23
CA2490847A1 (en) 2004-01-08
DE60313626D1 (en) 2007-06-14
DE60313626T2 (en) 2007-12-27
AU2003246920A1 (en) 2004-01-19
EP1539070A1 (en) 2005-06-15
ATE361046T1 (en) 2007-05-15
DK1539070T3 (en) 2007-09-17
US20040001880A1 (en) 2004-01-01
EP1539070B1 (en) 2007-05-02
AR039769A1 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
CA2490847C (en) Antimicrobial, silver-containing wound dressing for continuous release
US9610378B2 (en) Antimicrobial wound-covering material and method for manufacturing same
EP1216065B1 (en) Silver-containing compositions, devices and methods for making
AU2002219937B2 (en) Light stabilized antimicrobial materials
CN100394986C (en) Wound dressing containing Ag-Zn composition
US6605751B1 (en) Silver-containing compositions, devices and methods for making
JP4339592B2 (en) Medical bandages containing antimicrobial silver compounds
Ngece et al. Alginate-gum acacia based sponges as potential wound dressings for exuding and bleeding wounds
RU2422133C1 (en) Hydrophylic gel, method of its obtaining (versions), wound covering and based on it bandage means
CN101954117A (en) Hemostatic bacteriostatic biological dressing and preparation method thereof
MX2008011571A (en) Methods for producing silver-bonded antimicrobial moist wound dressings and moist wound dressings produced by the methods.
CN106994133A (en) Calcium zinc ion is combined antibacterial alginate slow-release material and preparation method thereof
Cao et al. Cerium oxide nanoparticle-loaded polyvinyl alcohol nanogels delivery for wound healing care systems on surgery
JPH04263855A (en) Wound coating material
Pu A dressing solution for burn wounds: antibacterial and low-adherent wound dressings
HU200092B (en) Process for production of dextrane perle-polimers for poudre for wounds suitable for improvement of its medical utilization

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/012644

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2490847

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003246920

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004516961

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003761700

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003761700

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003761700

Country of ref document: EP